(Q36501962)

14 August 2017

1 reference

title

Neurotransmitters and neuropeptides in Alzheimer's disease (English)

1 reference

14 August 2017

Neurotransmitters and Neuropeptides in Alzheimer's Disease (English)

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

26 October 2022

0 references

1 reference

2

Nemeroff CB

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1676509

26 October 2022

author name string

McDonald WM

1

1 reference

14 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1676509

26 October 2022

publication date

1 June 1991

1 reference

full work available at URL

14 August 2017

https://api.elsevier.com/content/article/PII:S0193953X18303162?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

https://api.elsevier.com/content/article/PII:S0193953X18303162?httpAccept=text/plain

26 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Psychiatric Clinics of North America

26 October 2022

published in

1 reference

14 August 2017

volume

14

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

421-442

1 reference

Changes in the brain catecholamines in patients with dementia of Alzheimer type.

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease

26 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia.

26 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia

26 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.

26 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin-like immunoreactivity within neuritic plaques

26 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Substance P immunoreactivity within neuritic plaques

26 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Red-cell/plasma choline ratio in dementia

26 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex

26 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex

26 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF somatostatin-like immunoreactivity in dementia

26 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in Alzheimer's disease

26 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex

26 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease

26 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease

26 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease

26 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression.

26 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations

26 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders.

26 October 2022

20

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia.

26 October 2022

21

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Oxytocin, vasopressin and memory: opposite effects on consolidation and retrieval processes

26 October 2022

23

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.

26 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Age and Histopathologic Heterogeneity in Alzheimer's Disease

26 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients.

26 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

26 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Growth hormone-releasing factor in mental disorders: a diagnostic marker and therapeutic alternative

26 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

GHRH-induced GH response in patients with senile dementia of the Alzheimer type

26 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia.

26 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neurons with galanin innervate cholinergic cells in the human basal forebrain and galanin and acetylcholine coexist

26 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia.

26 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cytology and distribution in normal human cerebral cortex of neurons immunoreactive with antisera against neuropeptide Y.

26 October 2022

36

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia

26 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

High-dose naloxone affects task performance in normal subjects

26 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in Alzheimer's disease

26 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

26 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type

26 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density.

26 October 2022

43

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neurotransmitter-related enzymes in senile dementia of the alzheimer type

26 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa

26 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type.

26 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptide Y-like immunoreactivity in neuritic plaques of Alzheimer's disease

26 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type

26 October 2022

50

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Increased corticotropin-releasing factor receptors in rat cerebral cortex following chronic atropine treatment

26 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease

26 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Central target for the behavioural effects of vasopressin neuropeptides

26 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

5 Neuropeptides and neurotransmitters in Alzheimer's disease: focus on corticotrophin releasing factor

26 October 2022

58

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alzheimer disease: lack of effect of lecithin treatment for 3 months.

26 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat

26 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in Alzheimer type dementia

26 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease

26 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin content and release measured in cerebral biopsies from demented patients.

26 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients

26 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia

26 October 2022

67

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients

26 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Vasopressin in affective illness

26 October 2022

69

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in Alzheimer's disease: evidence from chemical cross-linking studies.

26 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Preliminary Report: Intracranial Cholinergic Drug Infusion in Patients with Alzheimer's Disease

26 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptide-containing neurons of the cerebral cortex are also GABAergic

26 October 2022

75

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Antemortem markers of Alzheimer's disease

26 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography

26 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Effect of somatostatin (SRIF) and L-glutamate on neurons of the sensorimotor cortex in awake habituated rabbits

26 October 2022

79

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease.

26 October 2022

80

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides and cognitive disorders

26 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in aging and dementia.

26 October 2022

84

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Decreased level of β-endorphin-like immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type

26 October 2022

85

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Editorial: The prevalence and malignancy of Alzheimer disease. A major killer

26 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques

26 October 2022

88

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Depression in early-onset Alzheimer's disease: clinical and neuroendocrine correlates.

26 October 2022

92

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Growth hormone-releasing factor stimulation test in depression

26 October 2022

93

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Organization of galanin-immunoreactive inputs to the paraventricular nucleus with special reference to their relationship to catecholaminergic afferents

26 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Depression in Alzheimer's disease: an overview of adrenergic and cholinergic mechanisms

26 October 2022

95

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

The noradrenergic system in Alzheimer and multi-infarct dementias

26 October 2022

96

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit

26 October 2022

97

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Outcome of investigation of patients with presenile dementia.

26 October 2022

98

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and corticotropin (ACTH) are reduced in patients with Alzheimer's disease

26 October 2022

99

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Oxytocin in Alzheimer's disease: postmortem brain levels.

26 October 2022

100

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations

26 October 2022

104

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF vasopressin concentration is reduced in Alzheimer's disease.

26 October 2022

105

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

GABA-agonist therapy for Alzheimer's disease

26 October 2022

107

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients

26 October 2022

108

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Spinal fluid CRF reduction in Alzheimer's disease

26 October 2022

109

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin- and neuropeptide Y-immunoreactive neurons in the neocortex in senile dementia of Alzheimer's type

26 October 2022

110

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alzheimer's disease: a correlative study

26 October 2022

111

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in Alzheimer's disease: a postmortem study

26 October 2022

113

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Growth hormone response to growth hormone releasing factor in Alzheimer's disease.

26 October 2022

114

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

26 October 2022

115

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

26 October 2022

Endogenous opiates: 1983

116

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia

26 October 2022

117

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Presynaptic serotonergic dysfunction in patients with Alzheimer's disease

26 October 2022

118

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

26 October 2022

119

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

26 October 2022

120

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.

26 October 2022

121

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Multiple forms of somatostatin-like immunoreactivity are not influenced by cholinergic denervation of rat hippocampus

26 October 2022

122

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites

26 October 2022

123

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease.

26 October 2022

124

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer's disease

26 October 2022

125

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Decreased somatostatin-like immunoreactivity in cerebral cortex and cerebrospinal fluid in Alzheimer's disease.

26 October 2022

126

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Effects of naloxone in senile dementia: a double-blind trial.

26 October 2022

127

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Location of neuronal tangles in somatostatin neurones in Alzheimer's disease

26 October 2022

129

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Diagnostic Accuracy in Presenile Dementia

26 October 2022

130

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide.

26 October 2022

131

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type

26 October 2022

133

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

A post-mortem study of the cholinergic and GABA systems in senile dementia.

26 October 2022

134

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Arginine vasopressin and choline acetyltransferase in brains of patients with Alzheimer type senile dementia

26 October 2022

135

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Normal cortical concentration of cholecystokinin-like immunoreactivity with reduced choline acetyltransferase activity in senile dementia of Alzheimer type

26 October 2022

137

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus

26 October 2022

138

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

GABAergic neurons of mammalian cerebral cortex: Widespread subclass defined by somatostatin content

26 October 2022

139

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cholecystokinin octapeptide in dementia

26 October 2022

140

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF somatostatin in Alzheimer's disease.

26 October 2022

141

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease.

26 October 2022

142

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy

26 October 2022

143

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.

26 October 2022

144

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin- immunoreactive material

26 October 2022

145

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF and plasma vasopressin concentrations in dementia

26 October 2022

146

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptidergic systems in plaques of Alzheimer's disease

26 October 2022

148

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

26 October 2022

149

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases

26 October 2022

150

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Galanin impairs acquisition but not retrieval of spatial memory in rats studied in the Morris swim maze.

26 October 2022

151

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism

26 October 2022

153

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Choline chloride fails to improve cognition in Alzheimer's disease

26 October 2022

156

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Cell loss in the locus coeruleus in senile dementia of Alzheimer type.

26 October 2022

157

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

CSF vasopressin and cyclic nucleotide concentrations in senile dementia

26 October 2022

158

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

26 October 2022

160

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Neuropeptides. A new dimension in biological psychiatry

26 October 2022

162

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Possible significance of ACTH fragments for human mental performance

26 October 2022

163

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Somatostatin and (D-Trp8, D-Cys14)-somatostatin delay extinction and reverse electroconvulsive shock induced amnesia in rats.

26 October 2022

164

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Nicotinic acetylcholine binding sites in Alzheimer's disease

26 October 2022

166

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

26 October 2022

167

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy.

26 October 2022

168

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Dementia of different etiologies: vasoactive intestinal polypeptide in CSF

26 October 2022

169

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Reduced lumbar CSF somatostatin in levels in Alzheimer's disease

26 October 2022

171

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Overview of depression and psychosis in Alzheimer's disease

26 October 2022

172

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Choline metabolism in cholinergic neurons: implications for the pathogenesis of neurodegenerative diseases

26 October 2022

173

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Thyrotropin-releasing hormone, luteinizing hormone-releasing hormone and substance P immuno-reactivity in post-mortem brain from cases of Alzheimer-type dementia and Down's syndrome

26 October 2022

174

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

Major depression in primary dementia. Clinical and neuropathologic correlates

26 October 2022

175

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

The neuropathology of aminergic nuclei in Alzheimer's disease.

26 October 2022

176

1 reference

https://api.crossref.org/works/10.1016/S0193-953X(18)30316-2

26 October 2022

Identifiers

1 reference